Investigational Drug Information for Namilumab
✉ Email this page to a colleague
What is the drug development status for Namilumab?
Namilumab is an investigational drug.
There have been 7 clinical trials for Namilumab.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2022.
The most common disease conditions in clinical trials are Arthritis, Arthritis, Rheumatoid, and Sarcoidosis. The leading clinical trial sponsors are Takeda, Kinevant Sciences GmbH, and [disabled in preview].
There are two US patents protecting this investigational drug and twelve international patents.
Summary for Namilumab
| US Patents | 2 |
| International Patents | 12 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2022-04-01) |
| Vendors | 0 |
Recent Clinical Trials for Namilumab
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis | Kinevant Sciences GmbH | Phase 2 |
| A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis | Kinevant Sciences GmbH | Phase 2 |
| Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate | Takeda | Phase 2 |
Clinical Trial Summary for Namilumab
Top disease conditions for Namilumab
Top clinical trial sponsors for Namilumab
US Patents for Namilumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Namilumab | ⤷ Try a Trial | Cholestosome vesicles for incorporation of molecules into chylomicrons | THERASYN SENSORS, INC. (Eggertsville, NY) | ⤷ Try a Trial |
| Namilumab | ⤷ Try a Trial | Binding-triggered transcriptional switches and methods of use thereof | The Regents of the University of California (Oakland, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Namilumab
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Namilumab | Australia | AU2014236559 | 2033-03-14 | ⤷ Try a Trial |
| Namilumab | Brazil | BR112015022936 | 2033-03-14 | ⤷ Try a Trial |
| Namilumab | Canada | CA2905108 | 2033-03-14 | ⤷ Try a Trial |
| Namilumab | China | CN105164143 | 2033-03-14 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
